Recent developments in chemotherapy for bladder cancer.
Invasive bladder cancer is a chemotherapy-sensitive neoplasm. Historically, the development of cisplatin (Platinol)-based chemotherapy regimens has represented an important advance for patients with metastatic disease. More recently, investigations of new agents, such as gemcitabine (Gemzar) and paclitaxel (Taxol), have resulted in further options for these patients. Randomized trials comparing new regimens with cisplatin-based therapies have been initiated. The role of chemotherapy in the adjuvant and neoadjuvant settings is an area that is undergoing active investigation. The application of prognostic biological markers to risk-stratify patients has resulted in new avenues of investigation in these ongoing early disease trials.
Vaughn
D J
DJ
Department of Medicine Hematology-Oncology Division, University of Pennsylvania School of Medicine, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA.
Malkowicz
S B
SB
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage; D043823:Taxoids; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D000093542:Gemcitabine
D014408:Biomarkers, Tumor; D001952:Bridged-Ring Compounds; D043823:Taxoids; D003841:Deoxycytidine; C080625:taxane; D016190:Carboplatin; D017239:Paclitaxel; D000093542:Gemcitabine